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A number of cancers can follow an
indolent clinical course, even when the
disease is at an advanced stage. For exam-
ple, this pattern can be observed in some
patients with renal cell carcinoma (RCC),
breast cancer, and low grade non-Hodgkin
lymphoma (NHL). When systemic treat-
ments for these conditions are palliative,
chronic and often toxic, there is an argu-
ment for deferring therapy until there
is a clinically relevant burden of disease,
at which time the side effects of treat-
ment are counter-balanced by relief of
symptoms and disease control. A random-
ized trial of “watchful waiting” compared
to immediate chemotherapy treatment
in asymptomatic patients with low-grade
NHL found that overall survival between
these two groups was the same, and the
authors proposed that this approachmight
be particularly useful in elderly patients
(Ardeshna et al., 2003). Furthermore, pre-
liminary results of a randomized trial of
immediate rituximab (an anti-CD20mon-
oclonal antibody) versus a watch and wait
strategy in patients with asymptomatic
follicular lymphoma were presented and
indicate that rituximab significantly delays
the time to initiation of new therapy
such as chemotherapy or radiotherapy
(Ardeshna et al., 2010). It is important to
note that rituximab has a favorable side
effect profile, and the most powerful argu-
ment for a watchful waiting approach is
freedom from debilitating side effects and
preservation of quality of life for patients.
Prospective evidence for an initial
observational strategy in other solid tumor
types is limited, even though it is common
in clinical practice. It is well recognized
that a subgroup of patients with advanced
RCC has slowly progressive metastatic dis-
ease over a number of years. Metastatic
RCC (mRCC) was considered refractory to
systemic therapy for many years, but there
are now seven so called “targeted” agents
approved for this condition, which tar-
get the critical vascular endothelial growth
factor (VEGF) and mammalian target of
rapamycin (mTOR) pathways, leading to
inhibition of angiogenesis and cell sur-
vival and proliferation. All seven drugs
have been shown in randomized clini-
cal trials to significantly improve clini-
cal outcomes for patients with mRCC,
but they are non-curative and associated
in general with moderate toxicity. Up to
20% of patients appear to be primarily
refractory to these treatments (Rini and
Flaherty, 2008), and almost all patients
will eventually become resistant to an
individual drug, necessitating sequential,
chronic therapy. Because of the poten-
tial for substantial toxicity, a key ques-
tion in this field is the optimal time to
start treatment. It has been inferred from
a number of sources, including a ran-
domized discontinuation trial of sorafenib
(Ratain et al., 2006), that treatment delays
do not have an adverse impact but there
are no published data to support this
contention.
Recently, we conducted a retrospective
cohort study of patients treated at two cen-
ters to evaluate the clinical outcomes of
those patients with metastatic renal cell
cancer treated in the “targeted therapy
era,” in who first line systemic therapy was
deliberately deferred. Sixty-two patients
with mRCC who had a planned period of
observation prior to starting first line ther-
apy, because of asymptomatic or slowly
progressive disease, were included and the
primary objective was to determine the
progression free survival (PFS) of patients
on deferred first line systemic therapy.
All but one patient had favorable or
intermediate risk disease (63% and 36%
respectively), as defined by Heng et al.
(2009). On average, patients with mRCC
were observed for 18.7 months (95%
CI 14.5–22.0 months). After a period of
observation, 39 patients were treated with
sunitinib, 18 with interferon, and 5 with
other agents such as mTOR inhibitors.
Overall, the median PFS for patients on
first line therapy was 9 months (95%
CI 8.1–10.1 months). Patients treated
with sunitinib after observation also had
a median PFS of 9 months (95% CI
8.1–9.9 months), and those treated with
interferon had amedian PFS of 6.7months
(95%CI 0.7–12.7months). Median overall
survival, defined as the time from start-
ing first line treatment to death, was 25.2
months for all patients (95% CI 8.0–42.4
months), 17.4 months (95% CI 11.6–23.2
months) in the sunitinib group, and 37.6
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months (95% CI 2.6–72.5 months) in the
interferon group.
Thus, in this cohort of patients with
indolent, favorable or intermediate prog-
nosis mRCC, first line systemic therapy
was deferred by an average of more than
18 months and median PFS and overall
survival times were comparable to those
observed in the pivotal phase III and
expanded access trials of sunitinib (Motzer
et al., 2007; Gore et al., 2009).
Retrospective data such as these are
limited and clearly reflect selection bias.
However, they suggest that this practice
in mRCC is reasonable and does not
compromise outcome, and in our view,
there are compelling reasons for observa-
tional strategies to be prospectively, rig-
orously studied in this and other tumor
types. This would provide an opportu-
nity to evaluate longitudional quality of
life data using tools such as Quality-
adjusted Time Without Symptoms or
Toxicity (Q-TWiST), which incorporates
duration of survival and quality of life
experienced into a single endpoint (Cole
et al., 2004). It is possible that surveil-
lance only for advanced cancer results
in increased patient anxiety, and thus
harms quality of life, but this should
be prospectively assessed. Routine collec-
tion of tumor tissue from these patients
would enable investigation and validation
of biomarkers predictive of an indolent
clinical course, and importantly, this infor-
mation could be extrapolated for use in the
non-metastatic disease setting. For exam-
ple, observationmay also be appropriate in
those patients with incidental small renal
masses, particularly in the presence of
co-morbidities. Finally, an observational
strategy might result in more efficient use
of limited financial resources, a problem
which is now faced by almost all developed
countries.
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